ReviewFrontiers in psychiatry2024
Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review.
Review in Frontiers in psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Ketamine and esketamine during breastfeeding: a systematic review of human pharmacokinetic, infant and lactation outcomes.European journal of clinical pharmacology · 2026Pooled it
- Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis.Frontiers in psychiatry · 2026Pooled it
- Efficacy and safety of esketamine for pain control after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2025Pooled it
- Efficacy of perioperative esketamine on postoperative depression: a systematic review and meta-analysis.Frontiers in psychiatry · 2025Pooled it
- The median effective dose of esketamine with different doses of oliceridine during hysteroscopic surgery.Frontiers in pharmacology · 2025Trial
- Esketamine-based treatment, depression-specific metacognitive training, and their combination in treatment-resistant depression: 6-month trajectories of depressive symptoms and rumination in a multicenter observational study.European archives of psychiatry and clinical neuroscience · 2026Observational
- Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence.CNS drugs · 2026Review
- Neuroimmune Dysregulation and the Role of IL-10 in Depression: A Systematic Review.Brain sciences · 2026Review
- Effect of low-dose esketamine combined with labor analgesia on postpartum depressive symptoms following spontaneous labor: a randomized controlled trial.Frontiers in medicine · 2026Article
- Intranasal esketamine for ECT-refractory bipolar depression: a case report.Frontiers in psychiatry · 2026Article
- Article
- Euthanasia in Mental Disorders: Clinical and Ethical Issues in the Cases of Two Women Suffering from Depression.Healthcare (Basel, Switzerland) · 2025Article
- Towards an expanded neurocognitive account of ketamine's rapid antidepressant effects.The international journal of neuropsychopharmacology · 2025Review
- Research trends in esketamine for depression over the past decade: a bibliometric analysis.Frontiers in psychiatry · 2025Review
- Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression.Frontiers in psychiatry · 2025Article
- Safety and efficacy of esketamine combined with propofol or ciprofol sedation for electroconvulsive therapy in patients with major depressive disorder: protocol for a randomized, double-blind, controlled trial with factorial design.Frontiers in pharmacology · 2025Article
- Esketamine versus fentanyl as adjuncts to hepatic hilar nerve block for ambulatory percutaneous liver tumor ablation focusing on respiratory safety: protocol for a randomized controlled trial.Frontiers in pharmacology · 2025Article
- The perspectives of patients with depression toward esketamine, and the influence of their medication adherence on their viewpoints: a Saudi cross-sectional study.Frontiers in psychiatry · 2025Article
- Trends in research on novel antidepressant treatments.Frontiers in pharmacology · 2025Review
- Differential associations of serum globulin and albumin-globulin ratio with depression in cancer and non-cancer populations: a cross-sectional study.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and aims: Treatment-resistant depression (TRD) occurs when at least two different antidepressants, taken at the right dosage, for adequate period of time and with continuity, fail to give positive clinical effects. Esketamine, the S-enantiomer of ketamine, was recently approved for TRD treatment from U.S. Food and Drug Administration and European Medicine Agency. Despite proved clinical efficacy, many misconceptions by clinicians and patients accompany this medication. We aimed to review the most common "false myths" regarding TRD and esketemine, counterarguing with evidence-based facts. Methods: The keywords "esketamine", "treatment resistance depression", "depression", "myth", "mythology", "pharmacological treatment", and "misunderstanding" were entered in the main databases and combined through Boolean operators. Results: Misconceptions regarding the TRD prevalence, clinical features and predictors have been found. With respect of esketamine, criteria to start treatment, dissociative symptoms, potential addiction and aspects of administration and monitoring, were found to be affected by false beliefs by clinicians and patients. Discussion and conclusion: TRD represents a challenging condition, requiring precise diagnosis in order to achieve patient's full recovery. Esketamine has been proved as an effective medication to treat TRD, although it requires precautions. Evidence can inform clinical practice, in order to offer this innovative treatment to all patients with TRD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.